Clinical Trial Update: Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety and efficacy of evolocumab (REGN727/SAR236553) in heterozygous familial hypercholesterolemia; the trial is completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Hypercholesterolemia
• Hypercholesterolemia

Drugs mentioned

• Evolocumab (evolocumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Hypercholesterolemia | Phase 2 | Status: COMPLETED | Results posted: 2015-09-22